SELB - Selecta Biosciences, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.4900
-0.4100 (-21.58%)
As of 3:12PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close1.9000
Open1.4800
Bid1.49 x 3100
Ask1.50 x 4000
Day's Range1.4500 - 1.5300
52 Week Range1.4500 - 16.5450
Volume3,296,263
Avg. Volume284,680
Market Cap33.427M
Beta (3Y Monthly)2.62
PE Ratio (TTM)N/A
EPS (TTM)-3.14
Earnings DateNov 8, 2017 - Nov 13, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.00
Trade prices are not sourced from all markets
  • GlobeNewswire6 hours ago

    Selecta Biosciences Announces Pricing of Public Offering of Common Stock

    Selecta Biosciences, Inc. (SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR (SVP Rapamycin), today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock, at a public offering price of $1.50 per share, before underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $30.0 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the shares in the offering are to be sold by Selecta.

  • Benzinga8 hours ago

    The Daily Biotech Pulse: PTC Therapeutics, Select Biosciences Offering, Unity Biotech Expands Early-Stage Osteoporosis Drug Study

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peak (Biotech stocks hitting 52-week highs on Jan. 22) Veracyte Inc (NASDAQ: VCYT ) Down In The Dumps (Biotech ...

  • GlobeNewswire23 hours ago

    Selecta Biosciences Announces Proposed Public Offering of Common Stock

    Selecta Biosciences, Inc. (SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR (SVP Rapamycin), today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Canaccord Genuity and Needham & Company are acting as co-lead managers, and Janney Montgomery Scott is acting as co-manager for the offering. Selecta intends to use the net proceeds from the offering, in addition to its existing cash resources, to advance the clinical development of SEL-212, including the completion of a head-to-head superiority trial of SEL-212 compared to the current FDA-approved uricase therapy, completion of the Phase 2 clinical trial and preparations for a Phase 3 clinical trial, for other pre-clinical programs, including gene therapy development work, and for other operational activities and general corporate purposes.

  • Selecta Biosciences Enters Oversold Territory
    Zacks16 days ago

    Selecta Biosciences Enters Oversold Territory

    Selecta Biosciences, Inc. (SELB) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

  • Watertown biotech Selecta drops cancer drug, cuts staff
    American City Business Journals19 days ago

    Watertown biotech Selecta drops cancer drug, cuts staff

    Selecta Biosciences has announced plans to cut more than a third of its employees and shelve a cancer drug following various trial problems late last year. The Watertown biotech said it will eliminate 36 percent of its staff positions as part of a company restructuring. Selecta (Nasdaq: SELB) had 64 full-time employees as of January 2018, according to a federal filing.

  • GlobeNewswire20 days ago

    Selecta Biosciences Expands Potential for ImmTOR™ Platform and Streamlined Structure Under Leadership of New CEO, Carsten Brunn, Ph.D.

    “We believe 2019 will be a transformative year for Selecta with key milestones anticipated for both our chronic refractory gout and gene therapy programs. Based on interim data from the recently completed Phase 2 study, inclusive of the five outstanding patients who had not previously completed their course of therapy as of October 9th, 2018, 66% of evaluable patients (21/32), maintained serum uric acid (sUA) levels of

  • What Kind Of Shareholder Appears On The Selecta Biosciences Inc’s (NASDAQ:SELB) Shareholder Register?
    Simply Wall St.2 months ago

    What Kind Of Shareholder Appears On The Selecta Biosciences Inc’s (NASDAQ:SELB) Shareholder Register?

    Every investor in Selecta Biosciences Inc (NASDAQ:SELB) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insiders Read More...

  • GlobeNewswire2 months ago

    Selecta Biosciences Announces New Employment Inducement Grants

    Selecta Biosciences, Inc. (SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses, today announced that Carsten Brunn, Ph.D. commenced his services as the company’s Chief Executive Officer on December 1, 2018. In connection with the commencement of Dr. Brunn’s services, the company issued to Dr. Brunn an option to purchase an aggregate of 1,000,000 shares of the company’s common stock with a per share exercise price of $6.03, the closing trading price of the company’s common stock on the Nasdaq Global Market on November 30, 2018, and 175,000 restricted stock units.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of SELB earnings conference call or presentation 8-Nov-18 1:30pm GMT

    Q3 2018 Selecta Biosciences Inc Earnings Call

  • GlobeNewswire2 months ago

    Report: Developing Opportunities within Command Center, Neurotrope, Selecta Biosciences, InVivo Therapeutics, SeaSpine, and Senestech — Future Expectations, Projections Moving into 2018

    NEW YORK, Nov. 19, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • No. 1 Pharma Sees $1.5 Billion From Two Drugs — And It's Not Stopping There
    Investor's Business Daily2 months ago

    No. 1 Pharma Sees $1.5 Billion From Two Drugs — And It's Not Stopping There

    Horizon stock is catching the Street's eye on strong sales of its gout treatment and the potential for an eye disease drug. Horizon stock is up nearly 50% this year.

  • GlobeNewswire3 months ago

    Selecta Biosciences to Present at the Stifel Healthcare Conference 2018

    Selecta Biosciences, Inc. (SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses, today announced that CFO and Head of Corporate Strategy, John Leaman, M.D., will present at the Stifel Healthcare Conference in New York City at 12:45 p.m. ET on Tuesday, November 13, 2018. A live and archived webcast of the presentation can be accessed via the Investors & Media section of the company’s website, http://selectabio.com. Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. Selecta plans to combine its tolerogenic Synthetic Vaccine Particles (SVP™) to a range of biologics for rare and serious diseases that require new treatment options.

  • GlobeNewswire3 months ago

    Selecta Biosciences to Report Third Quarter 2018 Financial Results and Update on SEL-212 Development Strategy, including Planned Head-to-Head Study versus Krystexxa

    Selecta Biosciences, Inc. (SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses, today announced that it plans to issue its third quarter 2018 financial results before the open of the U.S. financial markets on Thursday, November 08, 2018.  The management team also plans to provide an update on the development strategy for SEL-212, the company’s lead product candidate for the treatment of chronic severe gout, including plans to conduct a head-to-head clinical trial of SEL-212 compared to the current FDA-approved uricase therapy, Krystexxa. Investors and the public can access a live and archived webcast of this call via the Investors & Media section of the company’s website, http://selectabio.com.

  • American City Business Journals3 months ago

    Selecta shares cut nearly in half since gout drug data

    Shares of the Watertown biotech continued to slide Wednesday, with the stock dropping more than 40 percent since the company presented new data on their gout drug earlier this week.

  • American City Business Journals3 months ago

    Watertown biotech Selecta halts cancer drug trial after patient dies

    According to the company, one patient died after developing pneumonitis, while a second developed a potentially life-threatening buildup of fluid around the heart.

  • Simply Wall St.4 months ago

    When Will Selecta Biosciences Inc (NASDAQ:SELB) Breakeven?

    Selecta Biosciences Inc’s (NASDAQ:SELB): Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company’s loss has recently Read More...